title: Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.
abstract: We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log(10) copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.
authors.affiliation: Brooke Army Medical Center, San Antonio, TX, United States.
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Stermole
authors.forename: Greg A
authors.initials: GA
authors.lastname: Grandits
authors.forename: Mollie P
authors.initials: MP
authors.lastname: Roediger
authors.forename: Brychan M
authors.initials: BM
authors.lastname: Clark
authors.forename: Anuradha
authors.initials: A
authors.lastname: Ganesan
authors.forename: Amy C
authors.initials: AC
authors.lastname: Weintrob
authors.forename: Nancy F
authors.initials: NF
authors.lastname: Crum-Cianflone
authors.forename: Tomas M
authors.initials: TM
authors.lastname: Ferguson
authors.forename: Grace E
authors.initials: GE
authors.lastname: Macalino
authors.forename: Michael L
authors.initials: ML
authors.lastname: Landrum
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D008297:Male; D008457:Measles / Q000517:prevention & control*; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D008889:Military Personnel; D009107:Mumps / Q000517:prevention & control*; D012189:Retrospective Studies; D012409:Rubella / Q000517:prevention & control*; D016036:Seroepidemiologic Studies; D014481:United States; D019562:Viral Load; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine